Clinical Trial

Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-324 in healthy volunteers (HV) and in patients with Hereditary Angioedema (HAE).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2023-01-10; most recent amendment 2026-06-12.
Status change: Recruiting → Active, Not Recruiting 2026-01-20
Trial Details
NCT Number NCT05691361
Lead Sponsor ADARx Pharmaceuticals, Inc.
Collaborators: Avance Clinical Pty Ltd.
Conditions Hereditary Angioedema
Enrollment 53 participants
Start Date 2022-12-14
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-16